Pharma's Market
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Existing-Home Sales Jump To Highest Level in 2-1/2 Years
- Paul: Audit the Fed
- Wave of Debt Payments Facing US Government
- Start-Up Proves Everything Really Is Better With Bacon
- TV Retailer QVC Joins 'Black Friday' Frenzy
- S&P Stocks Trading at New 52-Week Highs
- Buffett's Wealth and Fame Hasn't Helped 'Warren' As a Name
- Madoff—The Holiday Drink
- China Asks Its Banks to Slow Down
- Nov. 23: Unusual Volume Leaders
- Help Wanted—Please Run $4 Billion University
- Apple Comes to AT&T's Rescue
- Rally Could 'Have Some Legs in 2010': Market Strategist
- Investors May Skew Housing Reality
- Buffett's Wealth and Fame Hasn't Helped 'Warren' As a Name
- Are Crazy Retail Deals Good for Business?
- Expect a 'Square Root-Shaped' Recovery: Chief Investor
- Madoff—The Holiday Drink
- Why the Dollar Will Likely Stay Weak for Some Time
- Bear, Lehman Execs Weren't Wiped Out by Crisis: Study
- How Real Estate Investors Skew Housing's Reality
- Even Buffett's Huge Fame Can't Help the Name 'Warren'
- Wave of Debt Payments Facing US Government
- JPMorgan's Dimon Could Succeed Geithner: Report
- Suze Orman’s 'A Healthier, Wealthier You'
- Maria Blog: Are Crazy Retail Deals Good for Business?
- Latest Holiday Drinks: The Madoff...and the TARPatini
PHARMA'S MARKET VIDEO

Cholesterol Drug Battle: Niaspan vs. Zetia
16 Nov 2009
Cardiologist Grades Cholesterol Drug Study
16 Nov 2009
Merck's Cholesterol Drugs Under Pressure
16 Nov 2009
Cholesterol Drug Battle: Merck vs. Abbott Labs
16 Nov 2009
Cholesterol Drug Battle
16 Nov 2009
Novo Nordisk CEO on Diabetes Epidemic
13 Nov 2009
RSS FEED
Reporter
British drugmaker GlaxoSmithKline [GSK
Loading...
()
] is trying to keep from having to tighten its belt over new safety concerns with its weightloss pill, alli (rhymes with ally and the company oddly uses a lower case "a")
As European sales of the diet drug kicked in GSK sold $171 million worth of alli in the second quarter. That's not a lot of money for an industry that measures blockbuster drug sales by the billions, but it's big for an over-the-counter consumer product. In other words, it's a drug you don't need to get a prescription for. In the first quarter of this year the company posted alli sales of $42 million and in all of last year revenue came in at $139 million. So, even though the sales are relatively small, it's an important, fast-growing product.
Perhaps that explains why GSK came out last night with a pretty strongly worded statement essentially refuting a so-called "early communication" the FDA issued about alli on Monday. The agency says it has received 32 reports from people who took orlistat and who suffered "serious liver injury, including 6 cases of liver failure...." Orlistate is the scientific name for alli and Xenical, which is a prescription-strength version of it sold by Roche. The FDA says no cause and effect has been established at this point, but it's looking into the situation. In the meantime, it's telling people to simply take the drug as directed.
Glaxo says it "stands firmly behind the safety and efficacy of alli." It also claims that there's "no obvious biological mechanism to suggest liver damage can occur with alli." The company says it's monitoring and evaluating the liver damage reports but adds, "People who are overweight and obese are predisposed to liver-related disorders." But if you do a Google search under "alli lawsuits" a whole bunch of plaintiffs' lawyer websites come up with the new FDA information already.
Alli has a well-known, but nonetheless embarrassing and uncomfortable potential side effect. Let's just say the pamphlet that comes with the drug warns new patients to carry around a change of clothes.
Desperate dieters may have been willing to put up with that. The question now is whether publicity over a much more serious issue, albeit only suspected and as yet unproven, could scare them off.
fQuestions? Comments? and follow me on Twitter at mhuckman





